BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
July 2, 2007
View Archived Issues
Genmab 'Celebrating' Return Of Worldwide HuMax-CD4 Rights
Genmab A/S said it is moving full steam ahead with its late-stage HuMax-CD4 compound in cutaneous T-cell lymphoma after regaining full rights to the drug from partner Merck Serono SA. (BioWorld Today)
Read More
Cytokinetics' Ispinesib Mixed In Phase II Cancer Outcomes
Read More
Cutting Asymmetric DNA Is Basis For Potential HIV Cure
Read More
Peregrine Brings In $22.5M To Support Cancer, HCV Studies
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Appointments And Advancements
Read More